COVID-19 and Vaccine-Induced Thrombosis
Authors:
- Babak Sharif-KashaniBSBabak Sharif-Kashani
- Shadi ShafaghiSSShadi Shafaghi
- Farah NaghashzadehFNFarah Naghashzadeh
- Abdolreza MohamadniaAMAbdolreza Mohamadnia
- Mohammad RahdarMRMohammad Rahdar
- Maryam HajimoradiMHMaryam Hajimoradi
- Sima NooraliSNSima Noorali
Open Access
- Vol. 21 (4) , 413-418
Abstract
Coronavirus disease 2019 (COVID-19), a highly contagious infectious disease, has had a catastrophic effect on the world’s demographics resulting in more than 2.9 million deaths worldwide till January 2021. It can lead to systemic multi-organ complications; in particular, venous and arterial thromboembolism risk is significantly increased. Venous thromboembolism (VTE) occurs in 22.7% of patients with COVID-19 in the ICU and 8% in non-ICU hospitalized patients. Studies evaluating thromboprophylaxis strategies in patients with COVID-19 are needed to improve the prevention of VTE. VTE is the most commonly reported thrombotic complication, with higher incidence rates among critically ill patients. Several vaccines have been licensed and are currently used to combat the COVID-19 pandemic. Also, several cases of vaccine-induced thrombosis have been reported. Vaccination remains the most critical measure to curb the COVID-19 pandemic. There is a broad consensus that the benefits of vaccination greatly outweigh the potential risks of rare vaccine side effects, such as vaccine-induced immune thrombotic thrombocytopenia (VITT). Therefore, the importance of vaccination should be emphasized. This statement aims to focus on VITT.Keywords
This publication has 13 references indexed in Scilit:
- SARS-CoV-2 Vaccine–Induced Immune Thrombotic ThrombocytopeniaNew England Journal of Medicine, 2021
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationNew England Journal of Medicine, 2021
- Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care UnitJAMA, 2021
- Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT)Journal of Thrombosis and Haemostasis, 2021
- Covid-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds2021
- Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTHHamostaseologie, 2021
- Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysisResearch and Practice in Thrombosis and Haemostasis, 2020
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious ThromboprophylaxisHamostaseologie, 2020
- High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a reviewExpert Review of Hematology, 2019